Low-dose bevacizumab shows promise for managing ROP

• Posted on: Dec 12 2018
• By: Saratoga Opthalmology
• Leave a response

This study reports the recurrences of retinopathy of prematurity (ROP), follow-up treatments and retinal structure outcomes of patients after low-dose intravitreal bevacizumab.
Source: AAO

Posted in: Uncategorized